Management of Migraine Using Enerumab and Traditional Therapy at the Time of COVID-19

Inclusion Criteria: * -Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) * Sexes Eligible for Study: All * History of at least 5 attacks of migraine -≥ 15 headache days of which ≥ 8 headache days meet criteria as migraine days during the baseline period * chronic migraineurs with failure to more than 2 preventive treatments * chronic migraineurs without any preventive treatments * Naive to anti CGRP monclonal antibodies Exclusion Criteria: * Participants are excluded from the study if any of the following criteria apply: • unable to understand the study requirements, the informed consent, or complete headache records as required per protocol; * History of cluster or hemiplegic headache * Evidence of seizure or major psychiatric disorder Cardiac or active hepatic disease * pregnant, actively trying to become pregnant, or breast-feeding; * episodic migraineurs, * Other headache types * allergy to latex; * received nerve blocks or trigger point injections in the previous 8 weeks or plans to receive them during the study; * prior exposure in the last 6 months to biologics or drugs specifically targeting the calcitonin gene-related peptide (CGRP) pathway; * a psychiatric condition, that may affect the interpretation of efficacy and safety data or contraindicates the participant's participation in the study